Phase II Clinical Trial of Genexol -PM in Patients With Advanced Pancreatic Cancer
- Determine the time to progression and time to treatment failure in patients with
unresectable locally advanced or metastatic epithelial carcinoma of the pancreas
treated with paclitaxel loaded polymeric micelle (Genexol^®-PM).
- Determine the best overall response rate and duration of response in patients treated
with this drug.
- Determine the overall survival of patients treated with this drug.
- Determine the clinical benefit and safety of this drug in these patients.
OUTLINE: Patients receive paclitaxel loaded polymeric micelle (Genexol^®-PM) IV over 3 hours
on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable
PROJECTED ACCRUAL: A total of 43 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Time to progression
John S. MacDonald, MD
Beth Israel Comprehensive Cancer Center - West Side Campus
United States: Federal Government
|St. Vincent's Comprehensive Cancer Center - Manhattan||New York, New York 10011|
|Midwest Cancer Research Group, Incorporated||Skokie, Illinois 60077|
|Louisiana Oncology Associates - Lafayette||Lafayette, Louisiana 70506|
|Southwest Regional Cancer Center - Central||Austin, Texas 78705|
|Florida Cancer Specialists - Bonita Springs||Bonita Springs, Florida 34135|